文献速递肺血管病与心包/心肌炎血脂与心血管预防冠心病

外周动脉疾病患者的动脉粥样硬化风险与他汀使用

Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该回顾性队列研究纳入943232例有外周动脉疾病(PAD)、冠心病(CHD)或脑血管病史的成人,随访至2017年底。结果显示,仅PAD患者的年龄标准化ASCVD事件率为34.7/1000人年,高于仅CHD的42.2?不,原文仅PAD为34.7,仅CHD为42.2,仅脑血管病为38.9;但PAD患者他汀使用率仅33.9%,低于脑血管病(43.0%)和CHD(51.7%)。结论认为PAD患者ASCVD风险高但他汀使用不足,应加强他汀治疗。

要点

  • 仅PAD患者年龄标准化ASCVD事件率为34.7/1000人年(95%CI:33.2-36.2)。
  • 仅PAD患者他汀使用率33.9%,低于仅脑血管病(43.0%)和仅CHD(51.7%)。
  • 合并PAD、CHD和脑血管病三种情况者ASCVD事件率最高达119.5/1000人年。

核心结论

  • PAD患者尽管ASCVD事件风险高,但他汀使用率低于CHD或脑血管病患者,应加强他汀治疗。

研究设计与样本

  • 回顾性队列研究,纳入2014年12月31日有PAD、CHD或脑血管病史的≥19岁商业或Medicare保险成人943232例,随访至2017年12月31日。

主要发现

  • 有1、2、3种病史(包括PAD、CHD、脑血管病)的患者年龄标准化ASCVD事件率分别为40.8(95%CI:40.3-41.3)、68.9(95%CI:67.9-70.0)、119.5(95%CI:117.0-122.0)/1000人年。
  • 仅PAD、仅CHD、仅脑血管病患者ASCVD事件率分别为34.7(95%CI:33.2-36.2)、42.2(95%CI:41.5-42.8)、38.9(95%CI:37.6-40.1)/1000人年。
  • PAD+CHD、PAD+脑血管病、CHD+脑血管病患者ASCVD事件率分别为72.8(95%CI:71.0-74.7)、63.9(95%CI:60.6-67.4)、67.9(95%CI:66.4-69.3)/1000人年。
  • 仅PAD患者他汀使用率33.9%,低于仅脑血管病(43.0%)和仅CHD(51.7%)。

临床怎么用

  • 对PAD患者应评估并启动他汀治疗以降低ASCVD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral artery disease (PAD) is associated with increased risk for atherosclerotic cardiovascular disease (ASCVD) events. OBJECTIVES: The goal of this study was to compare the risk for ASCVD events and the use of statins among patients with PAD versus those with coronary heart disease (CHD) or cerebrovascular disease. METHODS: The authors conducted a retrospective cohort study of adults age ≥19 years with commercial or Medicare health insurance who had a history of PAD, CHD, or cerebrovascular disease on December 31, 2014. Patients were followed for ASCVD events comprising CHD, cerebrovascular disease, and PAD events until December 31, 2017. RESULTS: Among 943,232 patients included in the analysis, the age-standardized ASCVD event rate per 1,000 person-years for those with a history of 1, 2, and 3 conditions including PAD, CHD, and cerebrovascular disease was 40.8 (95% confidence interval [CI]: 40.3 to 41.3), 68.9 (95% CI: 67.9 to 70.0), and 119.5 (95% CI: 117.0 to 122.0), respectively. The ASCVD event rate among patients with PAD only, CHD only, and cerebrovascular disease only was 34.7 (95% CI: 33.2 to 36.2), 42.2 (95% CI: 41.5 to 42.8), and 38.9 (95% CI: 37.6 to 40.1), respectively. Among patients with PAD and CHD, with PAD and cerebrovascular disease, and with CHD and cerebrovascular disease, the ASCVD event rate was 72.8 (95% CI: 71.0 to 74.7), 63.9 (95% CI: 60.6 to 67.4), and 67.9 (95% CI: 66.4 to 69.3), respectively. Statin use was lower in patients with PAD only (33.9%) versus those with cerebrovascular disease only (43.0%) or CHD only (51.7%). CONCLUSIONS: Despite having high risk for ASCVD events, patients with PAD were less likely to be taking a statin versus those with CHD or cerebrovascular disease. ASCVD risk-reduction interventions including statin therapy in patients with PAD are warranted.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Colantonio LD, Hubbard D, Monda KL, et al. Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2020. PMID: 32674789. doi:10.1016/j.jacc.2020.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。